Skip to main content

Table 1 Alterations of TMEM240 in relation to the clinical parameters of Taiwan CRC cancer

From: Hypermethylation and decreased expression of TMEM240 are potential early-onset biomarkers for colorectal cancer detection, poor prognosis, and early recurrence prediction

CharacteristicsTotal naTMEM240 methylationbTotal nTMEM240 mRNAcTotal nTMEM240 protein
Low n (%), high n(%)Low n (%), high n (%)
Low n (%), high n (%)
Overall55671(12.8)485(87.2)12789(70.1)38(29.9)179131(73.6)47(26.4)
CRC54767(12.2)480(87.8)11885(72.0)33(28.0)141124(87.9)17(12.1)
Age
 < 6524028(11.7)212(88.3)0.7364429(66.9)15(34.1)0.15813296(72.7)36(27.3)0.656
> 6528536(12.6)249(87.4)6047(73.1)13(26.9)4635(76.1)11(23.9)
Sex
 Male31241(13.1)271(86.9)0.4095737(64.9)20(35.1)0.08412089(74.2)31(25.8)0.672
 Female21423(10.7)181(89.3)5443(79.6)11(20.4)5942(71.2)17(28.8)
Tumor type
 Adeno49158(11.8)433(88.2)0.35710376(73.8)27(26.2)0.2669084(93.3)6(6.7)0.189
 Others569(16.1)47(83.9)159(60.0)6(40.0)1916(84.2)3(15.8)
Tumor stage
 0 and I5311(20.8)42(79.2)0.04398(77.8)1(22.2)0.23866(100.0)0(0.0)0.450
 II, III, and IV44950(11.1)399(88.9)9869(70.4)29(29.6)10394(91.3)9(8.7)
Tumor size
 T0–T1344(11.8)30(88.2)0.93854(80.0)1(20.0)0.6641010(100.0)0(0.0)0.320
 T2–T448359(12.2)424(87.8)10071(71.0)29(29.0)9990(90.9)9(9.1)
Regional lymph nodes metastasis
 N = 026929(10.8)240(89.2)0.3095640(71.4)16(28.6)0.8976359(93.7)4(6.3)0.397
 N > 124834(13.7)214(86.3)5137(72.5)14(27.5)4641(89.1)5(10.9)
Distant metastasis
 M = 039645(11.4)351(88.6)0.2357655(72.4)21(27.6)0.7889285(92.4)7(7.6)0.026
 M > 110216(15.7)86(84.3)2821(75.0)7(25.0)4939(79.6)10(20.4)
Differentiation grade
 Well/moderate47959(21.4)420(87.7)0.58310073(73.0)27(27.0)0.5779183(91.2)8(8.8)0.448
 Poor333(9.1)30(90.9)65(83.3)1(16.7)66(100.0)0(0.0)
Location
 Cecum, appendix473(6.4)44(93.6)0.44986(75.0)2(25.0)0.89155(100.0)0(0.0)0.097
 Ascending colon889(10.2)79(89.8)108(80.0)2(20.0)2120(95.2)1(4.8)
 Transverse colon242(8.3)22(91.7)64(66.7)2(33.3)107(70.0)3(30.0)
 Descending colon479(6.4)38(80.9)95(55.6)4(44.4)98(88.9)1(11.1)
 Sigmoid colon16120(12.4)141(87.6)2718(66.7)9(33.3)3130(96.8)1(3.2)
 Rectum12913(10.1)116(89.9)1511(73.3)4(26.7)2019(95.0)1(5.0)
Vascular invasion
 No invasion40749(12.0)358(88.0)0.4585943(72.9)16(27.1)0.956     
 Invasion777(9.1)70(90.9)1813(72.2)5(27.8)     
MSI
 MSS503(6.0)47(94.0)0.4193727(73.0)10(27.0)0.630     
 MSI-L61(16.7)5(83.3)53(60.0)2(40.0)     
 MSI-H90(0.0)9(100.0)74(57.1)3(42.9)     
Tissue types
 Malignant          109100(91.7)9(8.3)< 0.001
 Metastasis          3224(75.0)8(25.0)
 Benign tumor94(44.4)5(55.6)94(44.4)5(55.6)103(30.0)7(70.0)
 Hyperplasia          81(12.5)7(87.5)
 Inflammation          105(50.0)5(50.0)
 Adjacent normal          115(45.5)6(54.5)
 Normal colon          82(25.0)6(75.0)
  1. These results were analyzed by the Pearson X2 test. Significant p values are indicated by superscripts
  2. aFor some categories, the number of samples (n) was lower than the overall number analyzed because clinical data were unavailable for those samples
  3. bThe TMEM240 promoter methylation level in CRC tumors being 5-fold higher than in adjacent normal colorectal tissues was defined as hypermethylation
  4. cThe TMEM240 expression level in CRC tumors being less than that of adjacent normal colorectal tissues was defined as low expression